预约演示
更新于：2025-06-23
Hydrocortisone Sodium Succinate
氢化可的松琥珀酸钠
更新于：2025-06-23
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H34NaO8 |
InChIKeyLGKJVUKNTHOZJH-CODXZCKSSA-N |
CAS号125-04-2 |
关联
30
项与 氢化可的松琥珀酸钠 相关的临床试验NCT06247787
A Phase 1 Study of GRN163L (Imetelstat) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia That is in Second or Greater Relapse or That is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or is Refractory to Relapse Therapy
NCT05761171
A Phase 2 Study of Revumenib (SNDX-5613) in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia
NCT05320380
A PedAL/EuPAL Phase 1/2 Trial of IMGN632 in Pediatric Patients With Relapsed or Refractory Leukemia
100 项与 氢化可的松琥珀酸钠 相关的临床结果
登录后查看更多信息
100 项与 氢化可的松琥珀酸钠 相关的转化医学
登录后查看更多信息
100 项与 氢化可的松琥珀酸钠 相关的专利（医药）
登录后查看更多信息
1,567
项与 氢化可的松琥珀酸钠 相关的文献（医药）2025-04-01EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
The assembled decoders to prepare for “bioactive X″ against progressive deterioration of liver disease: From NAFLD to HCC
Article
作者: Kim, Dong Joon ; Yoon, Sang-Jun ; Oh, Ki-Kwang ; Suk, Ki-Tae ; Kwon, Goo-Hyun ; Lee, Kyeong Jin ; Eom, Jung-A
Non-alcoholic fatty liver disease (NAFLD) is implicated in steatohepatitis (NASH), liver cirrhosis (LC) to hepatocellular carcinoma (HCC), sequentially. Herein, our aim was to unravel the nuanced key components (compounds, and targets) to deter the progressive severity concerning hepatocellular diseases. We incorporated rigor bioinformatics and computational screening tools to decode effector(s) against NAFLD, NASH, LC, and HCC. The corresponding ligands of PDX1 (transcription factor of INS; one agonist), and IL6 (thirty-two antagonists) were identified by Selleckchem. Molecular docking test (MDT) revealed that PDX1- BRD7552 conformer (-12.1 kcal/mol), and IL6- Forsythoside B (-11.4 kcal/mol) conformer formed most stable complex. In parallel, DFT proposed that BRD7552, and Forsythoside B had significant chemical properties to react the targets, respectively. In conclusion, we decoded causatives of the progressive liver disease with web-based tools in drug repositioning theory. BRD7552 as PDX1 agonist, and Forsythoside B as IL6 antagonist were attributed to synergistic efficacy against NAFLD-derived HCC.
2025-03-01SLAS Discovery
Heterotypic spheroids as a strategy for 3D culture of cryopreserved primary human hepatocytes in stirred-tank systems
Article
作者: Spangenberg, Thomas ; Arez, Francisca ; Alves, Paula M ; Gal, Isabella Ramella ; Preiss, Lena ; Rebelo, Sofia P ; Badolo, Lassina ; Brito, Catarina
Primary human hepatocytes (PHHs) are the preferred cell source to address liver function. Despite originating from the native tissue, one of the bottlenecks when using primary material is the donor-to-donor variability. Cryopreserved PHHs offer a high number of cells from the same donor and standardization of cell isolation and cryopreservation procedures, mitigating some of the inter-donor variability. Still, PHHs from different commercial sources present variability in vitro in several parameters, including viability post-thawing, plating capacity, aggregation potential and culture longevity. Here we combine stirred-tank culture systems, which allow robust aggregation processes, and co-culture approaches with the HepaRG cell line to generate spheroids from cryopreserved PHHs. By employing small-scale stirred-tank culture systems we could cope with the scarce availability and high cost of primary material. In the optimized co-culture conditions we could generate PHH:HepaRG spheroids from 12 donors acquired from 4 different commercial sources. All PHHs showed similar aggregation profiles, forming small compact heterotypic spheroids as early as 3 days in co-culture and were maintained for at least 5 weeks in culture. The heterotypic spheroids maintained the hepatocyte polarization and identity and showed metabolization capacity for 5 main phase I metabolizing enzymes, namely CYP3A4, CYP2C9, CYP1A2, CYP2D6, and CYP2C8. Moreover, the heterotypic spheroids showed the capacity to metabolize a novel compound under clinical development, showing their potential to be employed in drug discovery applications. Overall, we present a robust aggregation strategy for cryopreserved PHHs from different suppliers, applicable for pharmacological and toxicological in vitro research.
2025-01-01CONTACT DERMATITIS
Acute generalised exanthematous pustulosis induced by betamethasone sodium phosphate: A case report
Article
作者: Matsumoto, Ayaki ; Tateishi, Chiharu ; Hayashi, Eriko ; Tsuruta, Daisuke
Acute generalized exanthematous pustulosis (AGEP) is a type of severe drug eruption and is often induced by drugs.Although the number of cases is small, there are cases of AGEP induced by steroids.
100 项与 氢化可的松琥珀酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 哮喘 | 日本 | 1958-04-23 | |
| 创伤性休克 | 日本 | 1958-04-23 | |
| 沃-弗综合征 | 日本 | 1958-04-23 | |
| 过敏 | 美国 | 1955-04-27 | |
| 内分泌系统疾病 | 美国 | 1955-04-27 | |
| 眼部疾病 | 美国 | 1955-04-27 | |
| 血液疾病 | 美国 | 1955-04-27 | |
| 肾脏疾病 | 美国 | 1955-04-27 | |
| 肿瘤 | 美国 | 1955-04-27 | |
| 呼吸系统疾病 | 美国 | 1955-04-27 | |
| 风湿性疾病 | 美国 | 1955-04-27 | |
| 皮肤疾病 | 美国 | 1955-04-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 支气管肺发育不良 | 临床前 | 法国 | 2021-06-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 112 | Radiation Therapy+PEG-Asparaginase+Etoposide+doxorubicin+Hydrocortisone Sodium Succinate+6-MP+Methotrexate+Cytarabine+Methylprednisone+Cyclophosphamide+Imatinib+Dexamethasone+E. coli Asparaginase+Vincristine (Pre-amendment Cohort, 2500 IU/m2 q2 Weeks) | 鑰獵鏇壓艱鹽顧憲鹽廠 = 憲鬱簾遞顧蓋鹽範網糧 繭壓壓醖壓顧膚窪膚廠 (願鬱蓋窪鏇淵願鹹鬱窪, 壓構繭觸襯鏇夢鹽簾鹹 ~ 網繭膚憲願醖製觸廠蓋) 更多 | - | 2025-06-12 | ||
Radiation Therapy+PEG-Asparaginase+Etoposide+Doxorubicin+Hydrocortisone Sodium Succinate+6-MP+Methotrexate+Cytarabine+Methylprednisone+Cyclophosphamide+Imatinib+Dexamethasone+E. coli Asparaginase+Vincristine (Post-amendment Cohort, 2000 IU/m2 q3 Weeks) | 鑰獵鏇壓艱鹽顧憲鹽廠 = 簾壓構鹽蓋繭鬱選鬱夢 繭壓壓醖壓顧膚窪膚廠 (願鬱蓋窪鏇淵願鹹鬱窪, 觸鬱醖簾觸餘願製製淵 ~ 鏇範簾鹽夢窪積鑰遞鑰) 更多 | ||||||
N/A | - | Oral mixture of hydrocortisone sodium succinate and aluminum phosphate gel | 簾繭壓窪鏇鹹衊艱鹽艱(壓襯襯餘積選構製築繭) = 齋膚繭窪淵醖鹽觸鹽鑰 膚選遞憲鹽餘網憲觸壓 (憲憲遞積鹽餘選夢衊選, 1 ~ 1.8) 更多 | - | 2018-10-01 | ||
(EBD alone) | 簾繭壓窪鏇鹹衊艱鹽艱(壓襯襯餘積選構製築繭) = 積鬱餘遞餘夢廠選遞獵 膚選遞憲鹽餘網憲觸壓 (憲憲遞積鹽餘選夢衊選, 1 ~ 2.5) 更多 | ||||||
N/A | - | Endoscopic intralesional steroid injection + systemic steroid treatment | 築鏇築壓餘糧淵齋鹽鬱(築鹽餘簾鏇願遞糧襯蓋) = 窪觸築蓋齋構範醖網築 鑰範顧窪鏇憲艱襯餘窪 (醖鏇艱齋齋築艱願鬱願, 0 ~ 1) 更多 | - | 2018-10-01 | ||
Oral mixture of hydrocortisone sodium succinate and aluminum phosphate gel | 鏇醖製鏇衊窪築製鏇齋(鏇膚遞鏇網積製鏇齋糧) = 衊獵鹽築願壓襯獵艱遞 範觸獵壓簾夢夢廠醖積 (鑰糧願齋簾製襯夢網繭 ) | ||||||
临床2期 | 8 | 製餘齋繭鹹壓齋觸壓簾 = 襯蓋淵醖衊糧窪餘鏇獵 蓋鏇製鏇築衊製繭範蓋 (網膚遞鏇憲積餘夢繭顧, 衊鑰鏇鹽餘簾壓積鹹齋 ~ 顧憲夢艱鬱襯顧鹽範範) 更多 | - | 2017-11-22 | |||
N/A | - | Systemic steroid treatment (ST) | 夢餘鹹壓獵觸窪願繭夢(糧鑰襯蓋鹹顧糧廠膚衊) = 壓窪構鑰餘簾築積範壓 鹽廠願淵憲鏇願餘顧鏇 (餘觸選網簾網艱艱簾壓 ) 更多 | - | 2017-10-01 | ||
Endoscopic intralesional steroid (triamcinolone acetonide 80 mg) injection accompanied with systemic steroid treatment (IT + ST) | 夢餘鹹壓獵觸窪願繭夢(糧鑰襯蓋鹹顧糧廠膚衊) = 膚鏇壓憲範繭壓顧淵蓋 鹽廠願淵憲鏇願餘顧鏇 (餘觸選網簾網艱艱簾壓 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用